Glenmark Pharmaceuticals receives USFDA tentative approval for Dapagliflozin and Saxagliptin Tablets

Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg, the generic version of Qtern1 Tablets, 10 mg/5 mg, of AstraZeneca AB.

According to IQVIATM sales data for the 12 month period ending February 2020, the Qtern Tablets, 10 mg/5 mg market2 achieved annual sales of approximately $10.4 million.

Powered by Capital Market - Live News